Evidence map›Paper›PMID 35366279›Full record

ArticlePathophysiology : the official journal of the International Society for Pathophysiology2021

Interaction of TLK1 and AKTIP as a Potential Regulator of AKT Activation in Castration-Resistant Prostate Cancer Progression.

Md Imtiaz Khalil, Christopher Madere, Ishita Ghosh, Rosalyn M Adam, Arrigo De Benedetti

Abstract read
In one paragraph

Article in Pathophysiology : the official journal of the International Society for Pathophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Targeting PI3K/Akt signaling in prostate cancer therapy.Journal of cell communication and signaling · 2023
    Review
  6. Review
  7. Targeting Prostate Cancer, the 'Tousled Way'.International journal of molecular sciences · 2023
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Md Imtiaz KhalilLSU Health Sciences Center, Department of Biochemistry and Molecular Biology, Shreveport, LA 71103, USA.ORCID 0000-0003-0345-2101
Christopher MadereLSU Health Sciences Center, Department of Biochemistry and Molecular Biology, Shreveport, LA 71103, USA.
Ishita GhoshLSU Health Sciences Center, Department of Biochemistry and Molecular Biology, Shreveport, LA 71103, USA.
Rosalyn M AdamDepartment of Urology, Boston Children's Hospital and Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-0943-6236
Arrigo De BenedettiLSU Health Sciences Center, Department of Biochemistry and Molecular Biology, Shreveport, LA 71103, USA.

Funding

DOD Prostate Cancer Research Program W81XWH-17-1-0417
6 · The paper itself

Abstract

Prostate cancer (PCa) progression is characterized by the emergence of resistance to androgen deprivation therapy (ADT). AKT/PKB has been directly implicated in PCa progression, often due to the loss of PTEN and activation of PI3K>PDK1>AKT signaling. However, the regulatory network of AKT remains incompletely defined. Here, we describe the functional significance of AKTIP in PCa cell growth. AKTIP, identified in an interactome analysis as a substrate of TLK1B (that itself is elevated following ADT), enhances the association of AKT with PDK1 and its phosphorylation at T308 and S473. The interaction between TLK1 and AKTIP led to AKTIP phosphorylation at T22 and S237. The inactivation of TLK1 led to reduced AKT phosphorylation, which was potentiated with AKTIP knockdown. The TLK1 inhibitor J54 inhibited the growth of the LNCaP cells attributed to reduced AKT activation. However, LNCaP cells that expressed constitutively active, membrane-enriched Myr-AKT (which is expected to be active, even in the absence of AKTIP) were also growth-inhibited with J54. This suggested that other pathways (like TLK1>NEK1>YAP) regulating proliferation are also suppressed and can mediate growth inhibition, despite compensation by Myr-AKT. Nonetheless, further investigation of the potential role of TLK1>AKTIP>AKT in suppressing apoptosis, and conversely its reversal with J54, is warranted.

Indexed as

AKTIP/FT1/FTSapoptosiscastration-resistant prostate cancerPKB/AKTprostate cancerTLK1

Identifiers

PMID35366279
PMCPMC8830441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.